Celldex Therapeutics (CLDX) Return on Sales (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Return on Sales of 57.27% for Q1 2026, down 5637.0% year-over-year from 1.03% in Q1 2025, and down 532.14% quarter-over-quarter from 9.06% in Q4 2025.
Celldex Therapeutics (CLDX) Return on Sales (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 57.27% for Q1 2026.
- In Q1 2026, Return on Sales fell 5637.0% year-over-year to 57.27%; the TTM figure through Mar 2026 stood at 3.77% (down 311.0% YoY), while the FY2025 annual figure was 4.28%, down 360.0% from the prior year.
- Return on Sales for Q1 2026 stood at 57.27%, down from 9.06% in the prior quarter.
- The five-year high for Return on Sales was 0.15% in Q3 2024, with the low at 57.27% in Q1 2026.
- The 5-year median for Return on Sales is 0.95% (2023), against an average of 4.9%.
- The sharpest annual moves came in 2025 and 2026: Return on Sales jumped 181 bps in 2025, then slumped 5637 bps in 2026.
- Celldex Therapeutics' Return on Sales stood at 0.16% in 2022, then slumped by 476 bps to 0.95% in 2023, then tumbled by 206 bps to 2.9% in 2024, then plunged by 213 bps to 9.06% in 2025, then slumped by 532 bps to 57.27% in 2026.
- Business Quant data shows CLDX's Return on Sales at 57.27% in Q1 2026, 9.06% in Q4 2025, and 2.06% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -34.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.04% |
| Mar 31, 2026 | -57.27% |
| Dec 31, 2025 | -9.06% |
| Sep 30, 2025 | -2.06% |
| Jun 30, 2025 | -0.88% |
| Mar 31, 2025 | -0.90% |
| Dec 31, 2024 | -2.90% |
| Sep 30, 2024 | -0.15% |
| Jun 30, 2024 | -0.19% |
| Mar 31, 2024 | -2.71% |
| Dec 31, 2023 | -0.95% |
| Sep 30, 2023 | -0.27% |
| Jun 30, 2023 | -1.26% |
| Mar 31, 2023 | -0.33% |
| Dec 31, 2022 | -0.16% |
| Sep 30, 2022 | -0.66% |
| Jun 30, 2022 | -2.21% |
| Mar 31, 2022 | -1.32% |
| Dec 31, 2021 | -0.60% |
| Sep 30, 2021 | -1.34% |